November 27, 2021

FDA, J&J Near Deal for Covid-19 Vaccine Production at Baltimore Plant

WASHINGTON—The Food and Drug Administration and vaccine maker

Johnson & Johnson

JNJ -0.15%

expect to announce as early as next week that contamination problems at a Covid-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

Vaccine production at the plant run by contract manufacturer

Emergent BioSolutions Inc.

EBS 0.61%

was halted after unsanitary conditions led to contamination of J&J vaccines. The facility made vaccine substance and finished vaccine doses for J&J and

AstraZeneca

AZN 0.62%

PLC.

Emergent chief executive

Robert Kramer

told a House committee last week that the company had produced enough of a key ingredient to yield more than 100 million doses of the J&J vaccine.

The company has been taking corrective measures and been in talks with FDA and J&J over the steps needed to reopen the facility.

Johnson & Johnson said it is working with Emergent to secure “as quickly as possible emergency-use-authorization in the U.S. for Covid-19 drug substance manufactured at Emergent Bayview.”

Emergent declined to comment for this article.

The emergency use authorization for the plant to produce Covid-19 vaccine could be made next week, the U.S. officials said. That could help toward fulfilling

President Biden’s

pledges to share 20 million doses from J&J,

Pfizer Inc.

PFE -0.69%

and

Moderna Inc.

MRNA 2.25%

with the rest of the world by the end of June.

The Baltimore plant has produced millions of doses that were in inventory awaiting authorization, but most aren’t finished and are placed in vials, the officials said, adding it could take months before all those doses are ready for use.

One official said that as part of that arrangement to get the plant online, the U.S. and J&J have tentatively agreed that about 60 million doses of J&J vaccine substance made at the Baltimore plant now will be cleared for use either in the U.S. or overseas.

AstraZeneca is still doing testing on about 60 million doses, also manufactured at the Emergent plant in Baltimore, that could be the subject of another agreement with the FDA in coming weeks or possibly still part of this one, another official said. AstraZeneca declined to comment for this article.

The J&J doses, when they are finished, would be enough to vaccinate about 60 million people with the company’s one-shot regimen. The AstraZeneca doses, if they become available, are a two-dose regimen and could inoculate about half that many people.

An accident at the Baltimore plant led to the contamination of material that could have yielded up to 15 million doses during January and February.

An FDA inspection of the Emergent plant in April concluded that the facility failed to maintain clean and sanitary conditions and didn’t take proper measures to avoid cross-contamination between the two vaccine lines.

Under an agreement with the U.S. government, the U.S. had paid Emergent $271 million of monthly reservation fees to be prepared to manufacture vaccines, but the government partially stopped payment after learning of the contamination, according to a memo from the Democratic staff of the House Select Subcommittee on the Coronavirus Crisis.

At a meeting of the subcommittee last week, Emergent executives blamed some of the problems at its Baltimore vaccine plant on having to produce the two different vaccines simultaneously in large quantities.

Mr. Kramer said that “ramping up production of two novel vaccines on a very large scale in the same facility is unprecedented.”

In an April 30 response to the FDA inspection report, Emergent said it had decommissioned the AstraZeneca portion of its plant in the Bayview section of Baltimore and has taken several steps to avoid any contamination of the J&J vaccine ingredient.

It said it planned to complete several remedial steps, such as repairing, cleaning and disinfecting the manufacturing plant and improving training of personnel at the site.

The company pledged to take several corrective actions during May and June, all of which need to be accomplished before fully recommencing manufacturing at the site.

Write to Thomas M. Burton at tom.burton@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Japanese Business Leaders Add to Chorus Against Holding Olympics

May 24, 2021

May 24, 2021

TOKYO—Opposition to the Tokyo Olympics opening in two months has deepened in Japan and spread to some prominent business leaders...

Commodity Price Surges Add to Inflation Fears

June 7, 2021

June 7, 2021

The run-up in commodity prices is casting a cloud over the global economic recovery, slamming vulnerable businesses and households and...

China’s Campaign Against H&M Divides Fashion Industry Group

May 22, 2021

May 22, 2021

LONDON—A debate over how much to push back against the Chinese government has set off a conflict inside a prominent...

Teamsters Union Votes to Help Organize Amazon Workers

June 24, 2021

June 24, 2021

One of America’s largest labor unions passed a resolution Thursday designed to aid Amazon. AMZN -1.56% com Inc. workers in...

Amazon Policy Leads to Higher Consumer Prices, D.C. Suit Alleges

May 25, 2021

May 25, 2021

WASHINGTON—The District of Columbia filed an antitrust lawsuit against Amazon.com Inc. on Tuesday, alleging the company blocks sellers on its...

China’s Economic Growth Moderates as Consumers Stay Cautious

June 16, 2021

June 16, 2021

BEIJING—China’s economic growth moderated in May as flattering comparisons to the pandemic-hit economic figures early last year tapered off and...

Restaurants, Supermarkets Can’t Find Enough Workers to Open New Locations

June 3, 2021

June 3, 2021

The tight labor market is hampering new restaurant and supermarket openings, putting a potential check on growth in a food...

U.S. Wins International Backing for Global Minimum Tax

July 1, 2021

July 1, 2021

The U.S. has won international backing for a global minimum rate of tax as part of a wider overhaul of...

Rich Lesser, CEO Whisperer, on His Toughest Moments

June 25, 2021

June 25, 2021

Rich Lesser made a career advising CEOs. His own job as chief executive of Boston Consulting Group showed him the...

U.S. Added 850,000 Jobs in June

July 2, 2021

July 2, 2021

The U.S. added 850,000 jobs in June and the jobless rate was 5.9%, the Labor Department said Friday, as the...

Activist Investor Elliott Pushes Shake-Up at GlaxoSmithKline

July 1, 2021

July 1, 2021

Activist investor Elliott Management Corp. has intensified pressure on GlaxoSmithKline PLC, calling on the pharmaceutical giant to replace members of...

Entry-Level Lawyers Are Now Making $200,000 a Year

June 12, 2021

June 12, 2021

Salaries for junior lawyers are rising above $200,000 at many top law firms for the first time, following a year...

General Mills Warns of Inflation, Readies for Shifting Consumer Behavior

June 30, 2021

June 30, 2021

General Mills Inc. is bracing for an uncertain year as consumers emerge from spending more time at home during the...

The Pizza Business Is Divided on Delivery

May 30, 2021

May 30, 2021

The industry that pioneered delivery food is divided on whether to make its pies available through apps like DoorDash DASH...

Turbocharged U.S. Economy Attracts Foreign Investors

June 21, 2021

June 21, 2021

The extraordinary recovery of the U.S. economy is likely to make the country the world’s top destination for overseas investment...